Deal

BAXTER INTERNATIONAL INC acquires RECOTHROM and PREVELEAK products (from Mallinckrodt plc)

March 2018 asset purchase ready

Snapshot

BAXTER INTERNATIONAL INC acquired RECOTHROM and PREVELEAK products (from Mallinckrodt plc) for $184 million total consideration ($163 million upfront cash plus potential contingent payments) in March 2018. The transaction was structured as all cash (with contingent consideration). RECOTHROM and PREVELEAK products (from Mallinckrodt plc) is a Acquired from Mallinckrodt plc; products marketed primarily in the United States-based BioSurgery / hemostats and sealants business.

Acquirer
BAXTER INTERNATIONAL INC
Target
RECOTHROM and PREVELEAK products (from Mallinckrodt plc)
Value
$184 million total consideration ($163 million upfront cash plus potential contingent payments)
Date
March 2018
Type
asset purchase
Status
ready
01 Scorecard

The deal at a glance

Private-market deal
BAXTER INTERNATIONAL INC acquires RECOTHROM and PREVELEAK products (from Mallinckrodt plc)
Deal value
$184 million total consideration ($163 million upfront cash plus potential contingent payments)
Sector
BioSurgery / hemostats and sealants
Date
March 2018
VectorShift
Made on VectorShift

About this deal

BAXTER INTERNATIONAL INC acquired RECOTHROM and PREVELEAK products (from Mallinckrodt plc) for $184 million total consideration ($163 million upfront cash plus potential contingent payments), a transaction completed in March 2018, structured as all cash (with contingent consideration). The deal was a asset purchase.

RECOTHROM and PREVELEAK products (from Mallinckrodt plc) operates in BioSurgery / hemostats and sealants, is based in Acquired from Mallinckrodt plc; products marketed primarily in the United States, had revenue of about Contributed $52 million of net sales to Baxter in 2018 (partial year). RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant is used in vascular reconstruction; both hemostat and sealant products were acquired from Mallinckrodt plc.

Adds complementary hemostat and sealant products to Baxter's regenerative medicine and biosurgery franchise.

Complementary hemostat and sealant products extending Baxter's BioSurgery franchise. Integrated into Baxter's BioSurgery / Advanced Surgery business

On March 16, 2018, Baxter acquired two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant) and PREVELEAK Surgical Sealant for total consideration of $184 million.
Baxter FY2018 10-K, Acquisitions note
Advisors not disclosed

No advisory firms have been disclosed for this transaction.

Sources Press release Last updated

See how VectorShift works for your firm

Request Demo